Savara announces debt refinancing of $26.5m credit facility with silicon valley bank

Austin, texas--(business wire)--savara inc. (nasdaq: svra), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it entered into a term loan agreement of $26.5 million with silicon valley bank to replace its existing credit facility with the bank. the new facility represents a significant improvement in economic terms, including a lower interest rate compared to the existing loan rate and an initial 48-month interest only period. “we are pleased
SVRA Ratings Summary
SVRA Quant Ranking